Stent Tek, a London, UK-based medical device company, closed a Series A funding round of undisclosed amount.
Backers included Julz and Deepbridge Capital.
Led by Sorin Popa, co-Founder and CEO, Stent Tek is developing a novel catheter based system that aims to provide a safer and more efficient alternative for 2.8 million patients globally to receive haemodialysis for kidney failure. The single use ePATH AVF system uses a synthetic connector tube (covered stent graft) for creating a vascular access fistula in haemodialysis patients near the wrist level.
The company will use the funds to advance ePATH AVF. In order to develop it, Stent Tek previously received £1.2m in grant funding from the National Institute of Health Research (NIHR), Innovate UK, and the and the Royal Academy of Engineering Enterprise Hub. The company has validated the core functionality of the system in in-vivo models and anticipates the ePATH AVF catheter system will complete pre-clinical trials by Q4 2017.